137 Stock Chart & Stats
€1.26
€0.01(0.73%)
At close: 4:00 PM EDT
€1.26
€0.01(0.73%)
Day’s Range― - ―
52-Week Range€1.05 - €4.93
Previous CloseN/A
Volume1.95K
Average Volume (3M)102.00
Market Cap
€72.48M
Enterprise Value€83.54
Total Cash (Recent Filing)€45.09M
Total Debt (Recent Filing)€143.45K
Price to Earnings (P/E)―
Beta2.77
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,326,420
10 Day Avg. Volume75
30 Day Avg. Volume102
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.74Price Target Upside38.25% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)€1.08M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModest debt relative to equity indicates the company has not relied heavily on borrowing to fund operations. This preserves financial flexibility compared with a highly leveraged biotech and may leave more capacity to support development activities or address future funding needs.
2025 Loss ImprovementThe reduction in losses during 2025 provides evidence of some improvement in operating performance, even though the company remains unprofitable. If maintained, lower losses could extend available resources and reduce the pace at which external financing is required.
Governance StrengtheningAn independent audit committee chair can improve oversight of financial reporting, controls, and board accountability. Stronger governance is especially valuable for a development-stage biotech, where disciplined capital allocation and credible reporting support long-term execution.
Bears Say
No Demonstrated RevenueThe absence of reported revenue shows that the company has not yet demonstrated commercial demand or a self-sustaining revenue engine. This leaves future financial performance dependent on advancing development programs and ultimately achieving regulatory and commercial success.
Persistent Cash BurnPersistent negative operating and free cash flow means operations are being funded externally rather than by internally generated cash. The sharp deterioration in TTM outflows raises the risk that additional capital will be needed to sustain development and corporate activities.
Volatile Losses And Weak ReturnsRecurring losses and consistently negative returns on equity indicate that invested capital has not yet produced profitable returns. Unusually extreme TTM results also make earnings quality and trend interpretation less reliable, complicating planning and performance assessment.
Aldeyra Therapeutics News
137 FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was €1.05 and its highest was €4.93 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is €72.48M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 06, 2027 which is in 228 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Jul 31, 2026. The company reported -€0.078 earnings per share for the quarter.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,326,420 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -€0.078 in its last earnings report. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in DE:137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.74 (38.25% Upside)
€1.74 (38.25% Upside)
Blogger Sentiment
Bullish
DE:137 Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
137 Stock 12 Month Forecast
Average Price Target
€1.74
▲(38.25% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―